Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Tuesday after an insider sold shares in the company. $191.11 million flowed into the stock on the tick-up and $70.18 million flowed out of the stock on the tick-down, for a money net flow of $120.93 million into the stock. Of all equities tracked, Pfizer had the 5th highest net in-flow for the day. Pfizer traded down ($0.01) for the day and closed at $36.44Specifically, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mikael Dolsten sold 69,699 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the sale, the insider now owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 284,557 shares of company stock valued at $10,348,114. 0.06% of the stock is owned by corporate insiders.

A number of brokerages have commented on PFE. Societe Generale reiterated a “neutral” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Wednesday, May 30th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Wednesday, May 2nd. Jefferies Group reiterated a “neutral” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Monday, May 14th. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, BMO Capital Markets reduced their price objective on Pfizer from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $40.03.

The firm has a market cap of $215.79 billion, a price-to-earnings ratio of 13.75, a price-to-earnings-growth ratio of 1.80 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm had revenue of $12.91 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same period last year, the firm posted $0.69 EPS. The business’s revenue was up 1.0% on a year-over-year basis. equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 1st. Investors of record on Friday, May 11th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a yield of 3.73%. Pfizer’s dividend payout ratio is 51.32%.

Hedge funds have recently added to or reduced their stakes in the stock. Security Asset Management increased its stake in shares of Pfizer by 6.1% in the 4th quarter. Security Asset Management now owns 22,827 shares of the biopharmaceutical company’s stock valued at $827,000 after buying an additional 1,317 shares during the period. Waldron LP increased its stake in shares of Pfizer by 6.0% in the 4th quarter. Waldron LP now owns 23,785 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 1,341 shares during the period. Community Financial Services Group LLC increased its stake in shares of Pfizer by 0.6% in the 4th quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after buying an additional 1,375 shares during the period. TCI Wealth Advisors Inc. increased its stake in shares of Pfizer by 2.0% in the 4th quarter. TCI Wealth Advisors Inc. now owns 71,284 shares of the biopharmaceutical company’s stock valued at $2,582,000 after buying an additional 1,375 shares during the period. Finally, Banced Corp increased its stake in shares of Pfizer by 5.4% in the 4th quarter. Banced Corp now owns 26,667 shares of the biopharmaceutical company’s stock valued at $965,000 after buying an additional 1,376 shares during the period. 69.47% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.